DEF: Arcellx, Inc. Announces Annual Meeting of Stockholders and Executive Compensation Details

Arcellx, Inc. is holding its annual meeting of stockholders on May 28, 2025, to elect directors, approve executive compensation, and ratify the appointment of its independent accounting firm.

Summary

• Arcellx, Inc. will hold its annual meeting of stockholders virtually on May 28, 2025, at 1:00 pm ET.
• Stockholders of record as of April 4, 2025, are entitled to vote.
• The meeting will address the election of three Class III directors, an advisory vote on executive compensation (Say-on-Pay), and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board recommends voting FOR the election of the director nominees, FOR the Say-on-Pay proposal, and FOR the ratification of the accounting firm appointment.
• The proxy materials were first sent or given on or about April 17, 2025, and are accessible at www.proxydocs.com/ACLX.
• The document details the compensation of named executive officers (NEOs) including base salary, bonus, stock awards and option awards.
• The compensation committee aims to provide competitive compensation, link pay to performance, and align employee and investor interests.
• The company achieved 100% of its core performance goals and an additional 40% of its stretch goals in 2024, resulting in bonus payouts of 140% of target for NEOs.
• The document also discusses corporate governance practices, director independence, and related person transactions.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting the company's achievements and commitment to its mission. However, it also acknowledges certain challenges and risks, resulting in a moderately positive sentiment score.

Positives

• The company achieved 100% of its core performance goals and an additional 40% of its stretch goals in 2024.
• The company has a compensation recovery (clawback) policy in place.
• The company prohibits hedging and pledging of company securities by employees.
• The company is committed to diversity and inclusion within its workforce and clinical trials.
• The company has a highly engaged and high functioning board of directors and strong governance practices.

Negatives

• The Say-on-Pay proposal at the 2024 annual meeting received approximately 56.4% approval, indicating some stockholder concerns regarding executive compensation.
• One director, Ali Behbahani, serves on multiple public company boards, raising potential overboarding concerns, although the company believes his contributions are valuable.
• The company's net income was negative in 2022, 2023 and 2024.

Risks

• The document includes forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially.
• The company's success depends on the clinical development and commercialization of its product candidates, which are subject to regulatory approval and market acceptance.
• The company faces competition from other biotechnology and pharmaceutical companies.
• The company's financial performance is subject to various factors, including market conditions, regulatory changes, and technological advancements.

Future Outlook

The company is scaling its organization to deliver on its promise for patients, physicians, team members, and shareholders.

Management Comments

• On behalf of our Board of Directors, we would like to express our appreciation for your continued support of and interest in Arcellx.
• We are excited to carry this momentum into 2025 as we continue scaling our organization to deliver on the promise of Arcellx for our patients, physicians, team members and shareholders.

Industry Context

Arcellx operates in the competitive biotechnology industry, focusing on cell therapies. The company's success depends on its ability to develop and commercialize innovative products that address unmet medical needs.

Comparison to Industry Standards

• The compensation committee uses a peer group of publicly traded biotechnology and pharmaceutical companies to benchmark executive compensation.
• The peer group includes companies such as Akero Therapeutics, Allogene Therapeutics, Arcus Biosciences, and CRISPR Therapeutics.
• The company aims to position total cash compensation at the 50th percentile and long-term incentive compensation between the 75th and 90th percentiles of its peer group.
• The company's value-adjusted equity burn rate was 3.3% in 2024, below the ISS benchmark of 5.2% for Russell 3000 Biotechnology & Pharmaceuticals companies.
• Arcellx's Total Shareholder Return (TSR) for 2024 was 38%, compared to the average TSR of its peer group, which was -22%.

Management Changes

Corporate Governance

Related Party Transactions

• The company has entered into a Collaboration and License Agreement with Kite Pharma, Inc., a Gilead Company, and Gilead Sciences, Inc., a beneficial holder of more than 5% of the company's capital stock.
• The company has entered into an Amended and Restated Standstill and Stock Restriction Agreement with Gilead Sciences, Inc.

Stakeholder Impact

• The company's performance and executive compensation decisions impact shareholders, employees, and other stakeholders.
• The company is committed to building a diverse and inclusive organization, which benefits employees and the broader community.
• The company is dedicated to expanding representation within its clinical trials, which can contribute to addressing racial inequality in healthcare.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the proxy statement.
• The company will continue to advance its clinical programs and pipeline.
• The company will continue to monitor and adjust its executive compensation program as needed.

Key Dates

Keywords

executive compensation, annual meeting, proxy statement, board of directors, corporate governance, director election, PricewaterhouseCoopers, stockholders, Say-on-Pay, Arcellx